FRANKFORT, Ky. (KT) – The U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind device for the treatment of adult patients who have locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, non-invasive device that delivers alternating electrical fields, known as tumor treating fields (TTFields), to the abdomen. “Having treated many patients with pancreatic cancer, I know how difficult the diagnosis can be. The pancreatic cancer community deserves better therapeutic options,” said FDA Commissioner Marty Makary, M.D., M.P.H. Device treatment technological parameters are preset by the manufacturer and cannot be adjusted by the patient or physician.

Source: Daily Sun February 15, 2026 08:06 UTC